3 Canadian Healthcare Stocks With Revenue Growth Over 7%

Government borrowing costs sit at their highest levels in nearly two decades, which puts pressure on many sectors that rely heavily on debt. Canadian healthcare leaders with stronger balance sheets and steadier cash flows can look relatively more attractive when interest rates bite. This article walks through three of the strongest Canadian healthcare stocks from our quality screen so you can see how they stack up in this environment of higher rates.

The stocks covered below are just a starting sample from our quality screen, and the full list surfaced 2 more healthcare leaders with equally compelling stories that are not covered here. To identify your own high conviction opportunities across providers, equipment makers, pharma, biotech and health tech, analyze the Best Healthcare Stocks screener.

Aurora Cannabis (TSX:ACB)

Overview: Aurora Cannabis produces pharmaceutical-grade medical and consumer cannabis products and related patient services for healthcare markets in Canada and overseas.

Operations: Aurora Cannabis generates about CA$314 million from cannabis products, primarily across Canada, Europe, Australia and New Zealand medical-focused channels.

Market Cap: CA$375 million

Aurora Cannabis matters for this healthcare screen because its medical-grade cannabis and patient services put it closer to traditional pharma and providers than many peers.

"Expansion and leadership in fast-growing international medical cannabis markets, especially Europe (Germany, Poland, UK, Switzerland, Austria, France, Turkey, Ukraine) and Australia, positions Aurora to benefit from the accelerating global acceptance and regulatory normalization of medical cannabis, driving robust top-line revenue growth."

What happens to future margins and healthcare cash flows depends heavily on how one unseen regulatory and pricing pressure ultimately resolves.

Regulatory pressure cuts both ways. The full narrative for Aurora Cannabis explains how Aurora Cannabis could potentially turn that uncertainty into leverage if global medical access continues to accelerate.

Vitalhub (TSX:VHI)

Overview: Vitalhub delivers healthcare software that streamlines patient flow, electronic health records and care coordination for hospitals and community providers worldwide.

Operations: Vitalhub generates about CA$127 million from healthcare software, with key markets in the UK and Canada, plus Australia and smaller regions.

Market Cap: CA$467 million

Vitalhub matters for this Best Healthcare Stocks screen because its core platforms sit inside hospital and clinic workflows, helping providers move patients faster and document care more cleanly across busy systems.

"Ongoing increases in government funding for healthcare digital transformation, particularly large-scale tech budget expansions like the recent NHS investment, are providing new sales opportunities for Vitalhub's platform solutions (for example, Intouch, Zesty, MyPathway, Synopsis), directly supporting future recurring revenue growth."

What happens to Vitalhub’s margins and contract momentum may hinge on how one unresolved pressure on public health IT budgets eventually plays out.

That budget pressure is the real hinge, and the full narrative for Vitalhub shows how Vitalhub could keep recurring revenue accelerating while funding cycles stall elsewhere.

High Tide (TSXV:HITI)

Overview: High Tide runs cannabis retail and medical cannabis distribution, supplying licensed products and patient services across Canada and select international markets.

Operations: High Tide generates about CA$597 million from bricks and mortar operations, primarily in Canada with smaller contributions from international markets.

Market Cap: CA$355 million

High Tide interests healthcare focused investors because its medical cannabis distribution arm links directly to regulated patient treatment. The broader retail network and recent profitability may influence that segment’s development, depending on how one unseen pressure around future medical demand and pricing eventually plays out.

That future demand question is exactly what the analyst forecasts for High Tide unpack so you can see where High Tide’s medical and retail momentum may be quietly decoupling from peers.

Seeking Fresh Alternatives Beyond Healthcare?

Fresh ideas move first. Screen for shares showing early breakout momentum or quietly dropping into value territory before the crowd catches on and the window shrinks, act now.

• Scan for fast moving small caps where balance sheets already look battle tested using the curated 18 elite penny stocks with strong financials before that story gets fully priced in.
• Target potential compounders riding the build out of next gen infrastructure by running the focused 89 AI infrastructure stocks while these projects stay under the radar for now.
• Track cash producing miners that could benefit if metal sentiment turns by reviewing the hand picked 36 elite gold producer stocks while valuations still reflect recent caution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com